| Literature DB >> 28394705 |
Manas K Akmatov1,2,3, Peggy Riese4, Marcus May5, Leonhard Jentsch1, Malik W Ahmed1, Damaris Werner1, Anja Rösel1, Megan Tyler5, Kevin Pessler1, Jana Prokein6, Inga Bernemann6, Norman Klopp6, Blair Prochnow4, Stephanie Trittel4, Aravind Tallam1, Thomas Illig6, Christoph Schindler5, Carlos A Guzmán3,4, Frank Pessler1,2,3.
Abstract
Elderly individuals have the highest burden of disease from influenza infection but also the lowest immune response to influenza vaccination. A better understanding of the host response to influenza vaccination in the elderly is therefore urgently needed. We conducted a biphasic prospective, population-based study from Dec. 2014 to May 2015 (pilot study) and Sept. 2015 to May 2016 (main study). Individuals 65-80 y of age were randomly selected from the residents' registration office in Hannover, Germany, for the pilot (n = 34) and main study (n = 200). The pilot study tested recruitment for study arms featuring 2, 4, or 5 visits/blood draws. The 5-visit (day 0, 1/3, 7, 21, 70 with respect to vaccination) study arm was selected for the main study. Both studies featured vaccination with Fluad™ (Novartis, Italy), a detailed medical history, a physical exam, recording of adverse events, completion of a questionnaire on common infections and an end-of-study questionnaire, and blood samples. Response rates in the pilot and main studies were 3.7% and 4.0%, respectively. Willingness to participate did not differ among the study arms (Fisher's exact test, p = 0.44). In both studies, there were no losses to follow-up. Compliance with study visits, blood sampling and completion of the questionnaires was very high (100%, >97%, 100%, respectively), as were participants' acceptance of and satisfaction with both phases of the study. The low response rates indicate the need for optimized recruitment strategies if the study population is to be representative of the general population. Nonetheless, the complex prospective study design proved to be highly feasible.Entities:
Keywords: Germany; elderly; feasibility; influenza vaccination; nonresponse bias; pilot study; population-based study; response rate; vaccinomics
Mesh:
Substances:
Year: 2017 PMID: 28394705 PMCID: PMC5512809 DOI: 10.1080/21645515.2017.1299300
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN: 2164-5515 Impact factor: 3.452